To overcome the limitations of high-dose hIL-2 immunotherapy for metastatic cancer, different avenues have been pursued in the past years, including the development of muteins of IL-2 or its receptors as well as association of IL-2 to large molecules14–21. The gene discussed is IL2; the disease is metastatic malignant neoplasm.